Latest / The Well-Built Life / Weekly Wonders: HIV Treatment Evolution
Transcript
- 0:00Speaker 1: Hey, everyone, Welcome back to the Well Built Life. I
- 0:03Speaker 1: am Rachel Caldwell alongside Thomas Bennett, and we are so
- 0:07Speaker 1: glad you are tuning in. We are here to cut
- 0:09Speaker 1: through the noise, skip the intense jargon and extreme rules,
- 0:13Speaker 1: and share simple, practical habits that help you feel stronger,
- 0:17Speaker 1: healthier and more balanced every single day. Grab a drink,
- 0:21Speaker 1: get comfortable and let's dive in. So, Thomas, have you
- 0:25Speaker 1: seen the news about the new HIV treatment? The weekly
- 0:29Speaker 1: pill sounds like a real game changer, doesn't it?
- 0:31Speaker 2: Absolutely, Rachel, it's fascinating. The study just published by researchers
- 0:36Speaker 2: at Queen Mary's College in London is raising hopes that
- 0:39Speaker 2: people living with HIV might soon find it easier to
- 0:42Speaker 2: stick to their medication routine.
- 0:44Speaker 1: That's right right now, the daily pill is a huge commitment.
- 0:49Speaker 1: People have to remind themselves to take it every single day.
- 0:54Speaker 1: It's definitely a hassle, isn't it.
- 0:56Speaker 2: Exactly, especially for those dealing with the stigma of HIM
- 1:00Speaker 2: or other health conditions that require multiple medications. With a
- 1:04Speaker 2: weekly pill, the burden of treatment can become a lot
- 1:07Speaker 2: more manageable. It's all about reducing that daily reminder and
- 1:11Speaker 2: the hassle that comes with it.
- 1:13Speaker 1: Yes, and the study results are promising. It showed that
- 1:17Speaker 1: after forty eight weeks, a significant number of participants remained
- 1:21Speaker 1: virallly suppressed, just like those on the daily pill. This
- 1:25Speaker 1: means they can continue living their lives without the constant
- 1:28Speaker 1: worry of missing a dose.
- 1:30Speaker 2: That's the key advantage, less stress, more adherents. Skipping a
- 1:34Speaker 2: daily pill can really affect the treatment, especially if it's
- 1:38Speaker 2: a highly active undetectable state. With the weekly option, the
- 1:42Speaker 2: risk of treatment fatigue significantly decreases.
- 1:45Speaker 1: Speaking of which, treatment fatigue is a real thing. People
- 1:49Speaker 1: might skip doses and that can have serious health consequences.
- 1:53Speaker 1: If the pills are once a week, the temptation to
- 1:56Speaker 1: neglect them decreases, which is a major win for overall health.
- 2:00Speaker 2: True, and let's not forget the broader impact on quality
- 2:03Speaker 2: of life. For individuals dealing with the day to day
- 2:06Speaker 2: stress of their condition, a weekly pill could feel like
- 2:09Speaker 2: a much needed relief. It's not just about the medicine,
- 2:13Speaker 2: it's about making life easier.
- 2:14Speaker 1: Absolutely. Also, the stigma around HIV is still very real.
- 2:20Speaker 1: Any step that makes the treatment feel more normalized is
- 2:23Speaker 1: a positive step. This could help reduce the psychological burden
- 2:27Speaker 1: and improve overall well.
- 2:29Speaker 2: Being definitely, and this could be especially beneficial for those
- 2:33Speaker 2: living in areas with less access to healthcare. A pill
- 2:36Speaker 2: that's easier to manage might encourage more people to continue treatment,
- 2:40Speaker 2: which is critical for HIV control and prevention right and.
- 2:44Speaker 1: We know that keeping the virus undetectable not only benefits
- 2:47Speaker 1: the individual, but it also reduces the risk of transmission.
- 2:51Speaker 1: The weekly pill could help with both of these fronts
- 2:53Speaker 1: by improving adherents and managing the disease more effectively.
- 2:57Speaker 2: Will said, it's all about making the treatment as user
- 3:00Speaker 2: friendly as possible while still being effective. The research shows
- 3:04Speaker 2: to real potential here and it's exciting to see where
- 3:07Speaker 2: this can go in the future.
- 3:09Speaker 1: So Thomas, can we dive into the nuts and bolts
- 3:12Speaker 1: of the study? I heard there was quite a rigorous
- 3:14Speaker 1: methodology behind how they conducted this research at Queen Mary's College.
- 3:19Speaker 2: Absolutely, Rachel, It's fascinating. The researchers took a thoughtful, multi
- 3:24Speaker 2: pronged approach to ensure the study's results would be scientifically sound.
- 3:29Speaker 2: They recruited participants from twelve countries, which allowed for a
- 3:33Speaker 2: more diverse and representative sample.
- 3:35Speaker 1: Right, and this diversity is key because it mirrors the
- 3:39Speaker 1: real world scenario of people living with HIV. The study
- 3:43Speaker 1: included around six hundred HIV positive individuals who were already
- 3:48Speaker 1: virallly suppressed on their daily treatments.
- 3:50Speaker 2: Exactly. These participants were already on a stable daily treatment regimen,
- 3:55Speaker 2: meaning their viral loads were undetectable. Half of the participants
- 3:59Speaker 2: were there and switched to a once a week pill
- 4:01Speaker 2: combining islatravir and lenikopavir. The other half continued on their
- 4:06Speaker 2: daily pills as a control group.
- 4:07Speaker 1: And they tracked these people for forty eight weeks, right,
- 4:10Speaker 1: that's a significant amount of time to gather data. They
- 4:13Speaker 1: wanted to see if the switch to the weekly pill
- 4:16Speaker 1: would maintain the same levels of viral suppression.
- 4:18Speaker 2: Yes, precisely. Over this period, the study maintained strict monitoring,
- 4:24Speaker 2: including regular blood tests to check viral loads. At forty
- 4:28Speaker 2: eight weeks, they found that the viral suppression rates were
- 4:31Speaker 2: similar between the two groups. In other words, the once
- 4:35Speaker 2: a week pill performed as effectively as the daily pills.
- 4:38Speaker 1: That's promising, but let's break this down further. How did
- 4:42Speaker 1: they measure the success of the weekly treatment? I mean,
- 4:46Speaker 1: They didn't just rely on viral load, did they.
- 4:48Speaker 2: No, they didn't. They monitored a variety of factors. For instance,
- 4:53Speaker 2: they looked at factors like the level of drug in
- 4:55Speaker 2: the body, pharmacodynamics, the body's immune response, and the participants
- 5:00Speaker 2: effects and quality of life. They wanted to ensure the
- 5:02Speaker 2: weekly dosage was both effective and well tolerated.
- 5:06Speaker 1: Right and I gather. They also considered the mental burden.
- 5:10Speaker 1: For many taking a daily pill is a reminder and
- 5:13Speaker 1: can be stressful.
- 5:14Speaker 2: Absolutely, the study did consider the psychological aspect. The researchers
- 5:20Speaker 2: noted that although both groups experienced similar suppression rates, participants
- 5:25Speaker 2: on the weekly pill reported fewer treatment related stressors and
- 5:29Speaker 2: better adherents. Essentially, they felt the weekly pill provided a
- 5:33Speaker 2: sense of relief, which could lead to better long term compliance.
- 5:37Speaker 1: That's a crucial point. It's all about improving the quality
- 5:41Speaker 1: of life for these individuals. By reducing the number of pills,
- 5:45Speaker 1: they might feel more in control and less burdened.
- 5:48Speaker 2: Exactly, it's not just about the treatment itself, but how
- 5:52Speaker 2: it impacts people's lives. This study shows that by reducing
- 5:56Speaker 2: the treatment burden, we can potentially see better adherents and
- 6:00Speaker 2: overall well being.
- 6:01Speaker 1: It's exciting and it opens up possibilities for further research.
- 6:06Speaker 1: But how do you think this might play out in
- 6:08Speaker 1: the real world. What are the potential implications for public
- 6:12Speaker 1: health policies?
- 6:13Speaker 2: There are several potential implications. If the weekly pill works
- 6:17Speaker 2: as well as indicated, it could significantly improve patient adherence rates,
- 6:21Speaker 2: particularly among those experiencing treatment fatigue. This could have a
- 6:25Speaker 2: profound impact on the overall control of HIV as better
- 6:28Speaker 2: adherents means more people staying virally suppressed, which reduces the
- 6:32Speaker 2: risk of transmission. It's a positive move towards making HIV
- 6:36Speaker 2: treatment more user friendly and accessible for everyone.
- 6:40Speaker 1: So, Thomas, how do these weekly pills compare to the
- 6:43Speaker 1: long acting injectables that have already hit the market. What
- 6:48Speaker 1: are the main differences we should be aware of?
- 6:50Speaker 2: Great question, Rachel. Let's start with the dosage frequency. The
- 6:54Speaker 2: weekly oral pill takes the same approach as the daily
- 6:57Speaker 2: regimen in terms of how the medication works inside the bar.
- 7:00Speaker 2: It's just compressed into one tablet taken once a week.
- 7:04Speaker 2: On the other hand, the long acting injectibles provide sustained
- 7:07Speaker 2: release over a period of two months, so while both
- 7:11Speaker 2: aim to provide consistent treatment, the delivery method is quite different.
- 7:16Speaker 1: That makes sense, And how do these differences affect patient
- 7:20Speaker 1: preferences and uptake? I mean the convenience factor can be significant.
- 7:26Speaker 2: Indeed, convenience is a major factor. The long acting injectibles
- 7:30Speaker 2: have been promising in terms of reducing treatment fatigue, but
- 7:34Speaker 2: their higher cost and the need for a medical procedure
- 7:36Speaker 2: to administer them can be a barrier. Some patients might
- 7:40Speaker 2: find the weekly pill more appealing because it's easier to
- 7:43Speaker 2: manage at home and doesn't require as many visits to
- 7:46Speaker 2: the clinic.
- 7:47Speaker 1: Exactly, which brings up an interesting contradiction. In the study,
- 7:52Speaker 1: the weekly pill showed similar viral suppression rates to the
- 7:55Speaker 1: long acting treatment, but uptake might still lag. Why do
- 8:00Speaker 1: you think that is?
- 8:01Speaker 2: It's a good point, Rachel. One reason could be the
- 8:03Speaker 2: psychological factor of receiving an injection versus taking a pill.
- 8:08Speaker 2: People might still perceive the injectibles as more professional or serious,
- 8:12Speaker 2: even though both offer comparable benefits. Plus, we can't ignore
- 8:16Speaker 2: the initial hesitation some patients might have about switching from
- 8:19Speaker 2: a known daily routine to something new, no matter how
- 8:23Speaker 2: convenient it is.
- 8:24Speaker 1: That's a valid point, and to raise also the question
- 8:27Speaker 1: of stigma. For some, having a regular injection can be
- 8:31Speaker 1: less stigmatizing than a daily pill, especially when you consider
- 8:35Speaker 1: the social implications of being visibly sick or needing to
- 8:39Speaker 1: take medication every day.
- 8:40Speaker 2: Absolutely, the data from the CDC shows that only about
- 8:44Speaker 2: three percent of those on treatment in twenty twenty three
- 8:48Speaker 2: had switched to long acting injectibles. Many of them mentioned
- 8:52Speaker 2: feeling less stigma and more confidence with the injectible form.
- 8:56Speaker 2: This might be why the weekly pill could potentially see
- 8:59Speaker 2: better up todates.
- 9:00Speaker 1: So it sounds like the weekly pill could bridge some
- 9:03Speaker 1: of the gaps for those who are hesitant about the
- 9:05Speaker 1: long acting injectibles. But what about the potential drawbacks we
- 9:10Speaker 1: should consider?
- 9:11Speaker 2: That's a fair concern. The weekly pill might face its
- 9:14Speaker 2: own set of challenges. For instance, it's still a relatively
- 9:18Speaker 2: new treatment, and some patients might be wary of switching
- 9:21Speaker 2: to something that hasn't been around as long as daily
- 9:23Speaker 2: medications to raise. Also the issue of adherence. Some people
- 9:27Speaker 2: might miss a week's dose, which could impact viral suppression.
- 9:31Speaker 1: Right, and what about the broader public health implications? Will
- 9:35Speaker 1: the increased use of weekly pills or long acting injectibles
- 9:39Speaker 1: change how we approach HIV treatment in the future, definitely.
- 9:43Speaker 2: If the weekly pill gains widespread acceptance, it could shift
- 9:47Speaker 2: to paradigm from a daily to a more flexible regimen.
- 9:50Speaker 2: This aligns with a broader trend toward more user friendly treatments.
- 9:54Speaker 2: The long acting injectibles, while more established, might still hold
- 9:59Speaker 2: value for those who prefer the less frequent dosing. Both
- 10:03Speaker 2: methods could coexist and evolve as we learn more about
- 10:06Speaker 2: what works best for different patients.
- 10:09Speaker 1: That's a forward looking perspective. In essence, these innovations are
- 10:14Speaker 1: bringing us closer to a place where flexibility and convenience
- 10:18Speaker 1: are priorities for patients, all while maintaining the effectiveness of treatment.
- 10:23Speaker 2: Exactly, Rachel, It's about creating a system that's not only effective,
- 10:28Speaker 2: but also palatable for the individual patient, and that's ultimately
- 10:32Speaker 2: what will increase the uptake and make a real difference
- 10:35Speaker 2: in the lives of those living with HIV. Speaking of relief, Rachel,
- 10:39Speaker 2: the broader impact of moving from daily to weekly pills
- 10:42Speaker 2: extends far beyond just the convenience for patients. It's transforming
- 10:47Speaker 2: the patient management landscape in several significant ways.
- 10:50Speaker 1: Right, and that's the crucial nuance here. It's one thing
- 10:54Speaker 1: to reduce the pill burden for individuals, but it's quite
- 10:58Speaker 1: another to see how this impacts healthcare systems at large.
- 11:02Speaker 2: Absolutely, with fewer daily dosesterrees less strain on the patient's
- 11:07Speaker 2: cognitive and physical systems, It's not just about taking a
- 11:10Speaker 2: pill once a week. It's about reducing the daily emotional
- 11:14Speaker 2: and mental stress for people dealing with chronic illness. Let's
- 11:17Speaker 2: consider the ripple.
- 11:18Speaker 1: Effect exactly, which brings up an interesting contradiction. On one hand,
- 11:24Speaker 1: simplifying treatment can lead to improved adherence. On the other,
- 11:29Speaker 1: some might worry that reducing the frequency could dilute the
- 11:32Speaker 1: consistency of care.
- 11:34Speaker 2: That's a valid concern, However, the data from the Queen
- 11:37Speaker 2: Mary's College study suggests that patients remain virallly suppressed at
- 11:41Speaker 2: the same rates, if not higher, after the switch. The key,
- 11:45Speaker 2: as Professor Orkin pointed out, is in the pill design.
- 11:49Speaker 2: Both is latravir and lenakae pavere must be highly potent
- 11:53Speaker 2: to ensure safety and efficacy.
- 11:55Speaker 1: Right, But we are not just looking at adherence and effectiveness.
- 11:59Speaker 1: Are all also talking about stigma reduction. The daily pills,
- 12:03Speaker 1: especially for some people, are a constant reminder. Switching to
- 12:08Speaker 1: a once a week pill could make a profound difference.
- 12:11Speaker 2: Indeed, and it's not just about the stigma of taking medication,
- 12:15Speaker 2: it's the stigma of being HIV positive. Really, the more
- 12:19Speaker 2: discrete a treatment can be, the less visible the burden,
- 12:22Speaker 2: and the easier it can be to integrate into daily life.
- 12:25Speaker 2: That's a significant stride towards eradicating the stigma associated with HIV.
- 12:29Speaker 1: Absolutely, and let's not forget how this impacts healthcare systems.
- 12:34Speaker 1: Streamlining treatment can lead to savings both in clinical time
- 12:38Speaker 1: and costs. Providers can now focus on other areas of
- 12:42Speaker 1: patient care, making health care more efficient and less bureaucratic exactly.
- 12:47Speaker 2: The future possibilities are exciting. With more evidence and further research,
- 12:52Speaker 2: it's conceivable that we might see a broader shift towards
- 12:55Speaker 2: more convenient and effective treatment modalities. Maybe this will lead
- 13:00Speaker 2: to even longer acting treatments like monthly injections or even
- 13:04Speaker 2: oral treatments once a month.
- 13:05Speaker 1: That's wild when you look at the raw numbers. If widespread,
- 13:09Speaker 1: the switch could significantly reduce hospital visits and clinic appointments,
- 13:13Speaker 1: freeing up resources for other critical care needs. It's a
- 13:17Speaker 1: win for both patients and health care providers.
- 13:19Speaker 2: Right, And it's not just about the technical aspects. It's
- 13:22Speaker 2: about human dignity and quality of life. Reducing the complexity
- 13:27Speaker 2: of treatment regimens can empower patients to take more control
- 13:30Speaker 2: over their health, leading to better outcomes overall.
- 13:33Speaker 1: So, Rachel, what's the easiest step we can take today?
- 13:36Speaker 2: Well, Rachel, the simple answer is to stay informed, Share
- 13:40Speaker 2: this information with friends, family, and your local health care providers.
- 13:45Speaker 2: Advocate for more research and support for these types of treatments.
- 13:49Speaker 2: The more voices we have saying these things, the faster
- 13:52Speaker 2: progress we can make.
- 13:54Speaker 1: So, Thomas, what are the potential long term implications of
- 13:58Speaker 1: this weekly therapy for the broader HIV treatment landscape?
- 14:02Speaker 2: Rachel, that's a great question for starters. The potential for
- 14:06Speaker 2: weekly therapy is immense. It offers a compelling alternative to
- 14:10Speaker 2: both daily pills and long acting injectibles. The key here
- 14:13Speaker 2: is to understand that these weekly regimens could not only
- 14:16Speaker 2: improve patient adherents, but also help address treatment fatigue, which
- 14:20Speaker 2: is a significant issue.
- 14:22Speaker 1: Exactly, treatment fatigue can really affect adherence. I can see
- 14:26Speaker 1: why that's a big issue. So what do the latest
- 14:30Speaker 1: findings suggest for long term outcomes?
- 14:33Speaker 2: Well, the immediate outcomes from the study at Queen Mary's
- 14:36Speaker 2: College are promising. They showed that participants who switched from
- 14:40Speaker 2: daily to weekly pills maintained viral suppression rates similar to
- 14:44Speaker 2: those of their daily counterparts, but the lasting impact is
- 14:48Speaker 2: still being closely monitored. The researchers are following the participants
- 14:52Speaker 2: for a full ninety six weeks to assess safety and
- 14:55Speaker 2: long term effectiveness.
- 14:57Speaker 1: Right, and that's crucial because people are looking for assurance
- 15:01Speaker 1: that this weekly regimen is truly a step forward. So
- 15:06Speaker 1: what does the future hold for research in this area?
- 15:09Speaker 2: To raise a lot of potential here, Rachel, One of
- 15:12Speaker 2: the key areas of future research will be to understand
- 15:15Speaker 2: how this weekly therapy interacts with other health conditions. HIV
- 15:19Speaker 2: patients often have to manage multiple medications, and we need
- 15:22Speaker 2: to ensure that these weekly pills play nicely with their
- 15:25Speaker 2: other treatments.
- 15:26Speaker 1: Exactly and how can we make sure that this information
- 15:30Speaker 1: reaches the patients who need it most.
- 15:31Speaker 2: A crucial step is advocacy and education. We need to
- 15:35Speaker 2: make sure that healthcare providers are fully informed about the
- 15:38Speaker 2: potential benefits and any emerging challenges. They are the ones
- 15:42Speaker 2: who can provide the best guidance to their patients. Additionally,
- 15:46Speaker 2: patients support groups and nonprofits can play a vital role
- 15:50Speaker 2: in spreading awareness and connecting patients with the latest research findings.
- 15:54Speaker 1: That's a great point. So what's the easiest step we
- 15:57Speaker 1: can take today, Thomas? How can our listeners help move
- 16:01Speaker 1: this forward?
- 16:02Speaker 2: Well, Rachel, the simplest step is to stay engaged. Share
- 16:06Speaker 2: information about these developments with your network, including friends, family,
- 16:10Speaker 2: and your local health care providers. By being informed and vocal,
- 16:14Speaker 2: you can help push for more research and support for
- 16:16Speaker 2: weekly HIV treatments. Every voice counts.
- 16:20Speaker 1: Right, and that's the crucial nuance here. By keeping the
- 16:23Speaker 1: conversation alive, we can help drive progress. Let's make that
- 16:28Speaker 1: our mission.
- 16:28Speaker 2: Today absolutely, Rachel. Together we can make a real difference.
- 16:33Speaker 2: So let's keep pushing forward and supporting these critical developments.
- 16:37Speaker 1: That brings us to the end of today's episode. Thank
- 16:40Speaker 1: you so much for spending part of your day with me.
- 16:42Speaker 1: If you found this episode's tips helpful and want to
- 16:45Speaker 1: make sure you don't miss the next conversation, please take
- 16:48Speaker 1: a quick second to hit that subscribe or follow button
- 16:51Speaker 1: on whatever platform you are listening on. It's a completely
- 16:55Speaker 1: free way to support the show and helps more people
- 16:58Speaker 1: find us. This podcast is independently produced, so if you
- 17:01Speaker 1: are ever in a position where you would like to
- 17:03Speaker 1: help keep it running, we do accept small donations. You
- 17:07Speaker 1: can find a link right in the episode description below
- 17:10Speaker 1: to buy us a coffee or contribute what you can.
- 17:13Speaker 1: Every bit genuinely helps take care of yourself, stay balanced,
- 17:18Speaker 1: and we will talk again soon